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MaBACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is
unclear, and its risks and beneﬁts may vary according to DES generation.
OBJECTIVES The goal of this study was to evaluate the efﬁcacy and safety of DAPT after DES implantation.
METHODS We included randomized controlled trials that tested different durations of DAPT after DES implantation:
shorter dual antiplatelet therapy (S-DAPT) was deﬁned as the per-protocol minimum duration of DAPT after the procedure,
and longer dual antiplatelet therapy (L-DAPT)was deﬁned as the per-protocol period ofmore prolongedDAPT. The primary
efﬁcacy and safety outcomeswere deﬁnite/probable stent thrombosis and clinically signiﬁcant bleeding (CSB), respectively.
RESULTS Ten randomized controlled trials (N ¼ 32,135) were included. Compared with L-DAPT, S-DAPT had an overall
higher rate of stent thrombosis (odds ratio [OR]: 1.71 [95% conﬁdence interval (CI): 1.26 to 2.32]; p ¼ 0.001). The effect
of S-DAPT on stent thrombosis was attenuated with the use of second-generation DES (OR: 1.54 [95% CI: 0.96 to 2.47])
compared with the use of ﬁrst-generation DES (OR: 3.94 [95% CI: 2.20 to 7.05]; p for interaction ¼ 0.008). S-DAPT had
an overall signiﬁcantly lower risk of CSB (OR: 0.63 [95% CI: 0.52 to 0.75]; p < 0.001). Finally, a numerically lower
all-cause mortality rate was observed with S-DAPT (OR: 0.87 [95% CI: 0.74 to 1.01]; p ¼ 0.073).
CONCLUSIONS S-DAPT had overall lower rates of bleeding yet higher rates of stent thrombosis compared with L-DAPT;
the latter effect was signiﬁcantly attenuated with the use of second-generation DES, although the analysis may have been
limited by the varying DAPT durations among studies. All-cause mortality was numerically higher with L-DAPT without
reaching statistical signiﬁcance. Prolonging DAPT requires careful assessment of the trade-off between ischemic and
bleeding complications. (J Am Coll Cardiol 2015;65:1298–310) © 2015 by the American College of Cardiology Foundation.A period of dual antiplatelet therapy (DAPT) isrequired to prevent thrombotic complica-tions after percutaneous coronary inter-
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
CSB = clinically
signiﬁcant bleeding
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
L-DAPT = longer dual
antiplatelet therapy
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous
coronary intervention
RCT = randomized
controlled trial
S-DAPT = shorter dual
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1299The pathobiological rationale of DAPT after DES-PCI
is based on the need to protect the stented vascular
segment from the development of stent thrombosis
while vascular healing and progressive strut endothe-
lization are ongoing (5). In addition, more prolonged
DAPT may confer protection from atherothrom-
botic events occurring outside the stented segment
throughout the coronary vasculature (6).
Prolonged DAPT after the recommended period re-
duces stent-related and non–stent-related adverse
ischemic events following PCI (7). Recently, the DAPT
(Dual Antiplatelet Therapy) trial demonstrated reduced
rates of stent thrombosis and myocardial infarction (MI)
with DAPT extended beyond 1 year after DES implanta-
tion. However, this ischemic beneﬁt was paired with an
increased risk in bleeding and possibly subsequent all-
cause mortality.SEE PAGE 1311
antiplatelet therapy
TIMI = Thrombolysis In
Myocardial Infarction
Several randomized controlled trials (RCTs) have
attempted to address the question of what would be
the safest and shortest DAPT duration (ranging from
3 to 6 months) after implantation of ﬁrst- and second-
generation DES. Due to the rarity of stent thrombosis
events, each trial had limited statistical power, and
the safest and shortest DAPT duration has not yet
been reliably determined. Previously published meta-
analyses of RCTs comparing short- versus long-term
DAPT had limited statistical power and showed no
signiﬁcant differences in antithrombotic efﬁcacy be-
tween regimens,while longer dual antiplatelet therapy
(L-DAPT) treatment was associated with an increased
risk for bleeding (8,9). With inclusion of several recent
large RCTs, the present meta-analysis has enhanced
statistical power, and we therefore sought to assess
the efﬁcacy and safety of shorter dual antiplatelet
therapy (S-DAPT) versus L-DAPT after DES implanta-
tion, with particular focus on the risk of stent throm-
bosis with the use of current (second-generation) DES.
METHODS
Study groups were pre-speciﬁed as follows: S-DAPT,
deﬁned as the per-protocol minimum duration of
DAPT after DES implantation (after which, patients of
this treatment arm were continued on aspirin alone);
and L-DAPT, deﬁned as the per-protocol period
of prolonged DAPT in each trial. In addition, RCTs
evaluating durations of DAPT were classiﬁed as
abbreviated-term DAPT studies (i.e., RCTs evaluating
S-DAPT duration of 3 or 6 months vs. longer duration)
and extended-term DAPT studies (i.e., RCTs evalu-
ating DAPT discontinuation at 12 months vs. longer
duration).The pre-speciﬁed primary efﬁcacy out-
come was the incidence of deﬁnite or prob-
able stent thrombosis, as deﬁned by using the
criteria of the Academic Research Consortium
(10). The main safety outcome was clinically
signiﬁcant bleeding (CSB), deﬁned as a
bleeding event fulﬁlling the deﬁnition of:
1) minor or major Thrombolysis In Myocardial
Infarction (TIMI) bleeding; 2) type 3 or 5
bleeding according to the Bleeding Academic
Research Consortium (BARC); 3) Safety and
Efﬁcacy of Enoxaparin in Percutaneous Cor-
onary Intervention Patients major bleeding;
or 4) Global Use of Strategies to OpenOccluded
Arteries moderate or severe bleeding (11).
Bleeding deﬁnition details are described in
Online Table 1. Additional outcomes of in-
terest were MI, stroke, cardiovascular death,
and all-cause mortality. Outcomes were re-
ported at the maximum time of follow-up
available (Table 1). The study was performed
according to the Quality of Reporting of Meta-
Analysis statement (12).
MEDLINE, Scopus, the Cochrane Library, and
Internet sources were searched for abstracts, manu-
scripts, and conference reports; there were no lan-
guage or date restrictions. All the RCTs comparing
different durations of DAPT after implantation of a
DES were included in the meta-analysis. The ﬁnal
search yielded 10 RCTs comparing various durations
of S-DAPT and L-DAPT after implantation of different
types of DES.
DATA EXTRACTION. Two investigators indepen-
dently reviewed the studies and reported the
results in a structured dataset. Disparities between
investigators regarding the inclusion of each trial
were resolved by consensus by a third independent
investigator. Pre-speciﬁed data elements were ex-
tracted from each trial; these elements included
S-DAPT and L-DAPT duration, maximum length of
follow-up, sample size, baseline characteristics,
outcome measures, and endpoints of interest. Events
from each trial were recorded according to the
intention-to-treat principle. Endpoint deﬁnitions
used in each trial are outlined in Online Table 2.
STATISTICAL ANALYSIS. The odds ratios (ORs)
associated with S-DAPT versus L-DAPT from the
abstracted data were estimated. Analyses were
stratiﬁed according to DAPT trial type (abbreviated-
term and extended-term DAPT studies). The average
effects for the outcomes and 95% conﬁdence intervals
(CIs) were calculated by means of random effects
models according to the method of DerSimonian
TABLE 1 Characteristics of the Randomized Clinical Trials
Study (Ref. #) Year
Study
Population (n)
S-DAPT
(Months)
L-DAPT
(Months)
Time of
Follow-Up*
Placebo-
Controlled Primary Endpoint
Age
(yrs)
DM
(%)
ACS
(%)
1G-DES
(%)
2G-DES
(%)
3- or 6-month DAPT discontinuation trials
ISAR-SAFE (16) 2014 4,000 6 12 6 Yes Composite of death, MI, stroke,
stent thrombosis, or TIMI major
bleeding at 15 months after PCI
67 25 40 10 89
ITALIC (17) 2014 1,822 6 12 6 No Composite of death, MI, repeat TVR,
stroke, or TIMI major bleeding
at 12 months after PCI
62 37 24 — 100†
SECURITY (18) 2014 1,399 6 12 12‡ No Composite of cardiac death, MI,
stroke, stent thrombosis, or BARC 3
or 5 bleeding at 12 months after PCI
65 31 38§ — 100
OPTIMIZE (15) 2014 3,119 3 12 12 No Composite of death, MI, stroke, or major
bleeding at 12 months after PCI
62 35 32§ — 100
PRODIGY (20) 2012 1,970 6 24 23 No Composite of death, MI, or
cerebrovascular accidents
at 24 months after PCI
68 24 75 25 50
EXCELLENT (19) 2011 1,443 6 12 12 No Composite of cardiac death, MI, or
TVR at 12 months after PCI
63 38 52 25 75
RESET (14) 2012 2,117 3 12 12 No Composite of cardiac death, MI,
stent thrombosis, ischemia-driven TVR,
or bleeding at 12 months after PCI
62 29 54 21 85k
12-month DAPT discontinuation trials
DAPT (7) 2014 9,961 12 30 21 Yes Stent thrombosis; composite of
death, MI, or stroke; and moderate
or severe GUSTO bleeding;
at 18 months after randomization
62 31 43 38 60
DES-LATE (22) 2014 5,045 12 36 42 No Composite of cardiac death, MI, or
stroke at 24 months after randomization
62 28 61 64 30
ARCTIC-Interruption
(21)
2014 1,259 12 18–30 17 No Composite of death, MI, stroke or TIA,
urgent revascularization, or
stent thrombosis
64 34 — 40 63
*Refers to follow-up time from randomization (Online Figure 1 and Figure 2). †Only Xience V everolimus-eluting stent. ‡Maximum length of follow-up was 24 months; however, maximum duration of DAPT
was 12 months. In the analyses, outcomes at 12 months have been included. §High-risk acute coronary syndromes excluded. k100% Endeavor zotarolimus-eluting stent in the 3-month group.
1G ¼ ﬁrst-generation; 2G ¼ second-generation; ACS ¼ acute coronary syndrome; ARCTIC-Interruption ¼ Dual-Antiplatelet Treatment Beyond 1 Year After Drug-Eluting Stent Implantation; BARC ¼
Bleeding Academic Research Consortium; DAPT ¼ dual antiplatelet therapy; DES ¼ drug-eluting stent; DES-LATE ¼ Duration of Clopidogrel Therapy After Drug-Eluting Stent; DM ¼ diabetes mellitus;
EXCELLENT ¼ Efﬁcacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; GUSTO¼ Global Use of Strategies to Open Occluded Arteries; ISAR-SAFE ¼ Safety and Efﬁcacy of Six Months Dual
Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC ¼ Is There A Life for DES After Discontinuation of Clopidogrel; L-DAPT ¼ longer dual antiplatelet therapy; MI ¼ myocardial infarction; OPTIMIZE ¼
Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice; PCI ¼ percutaneous coronary intervention; PRODIGY ¼ Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; RESET ¼ REal Safety and Efﬁcacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent
implantation; S-DAPT ¼ shorter dual antiplatelet therapy; SECURITY ¼ Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Antiplatelet Therapy; TIA ¼ transient
ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction; TVR ¼ target vessel revascularization.
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conducted by using Harbord’s modiﬁed test. Hetero-
geneity among trials for each outcome was calculated
by means of I2 test.
To assess the trade-off between stent thrombosis
and CSB over time, the incidence rates of adverse
events and corresponding incidence risk differences
between groups were analyzed, taking into account
the variable follow-up times within each study. To do
so, we calculated stent thrombosis and CSB incidence
rates per 100 person-years within each exposure
group (S-DAPT and L-DAPT). The exposure time was
calculated based on the mean follow-up time for each
trial. The overall standardized incidence risk differ-
ence was calculated by assigning a weight to each
RCT equal to the inverse of the variance of the effect
estimate.
To evaluate the effects of DES generation on stent
thrombosis, the results were stratiﬁed accordinglyby using stent-level data when available (ﬁrst-
vs. second-generation DES). Studies in which the
numbers of events with each speciﬁc DES type
were not available were excluded from this analysis.
First-generation DES included sirolimus-eluting and
paclitaxel-eluting DES; second-generation DES in-
cluded everolimus-eluting and zotarolimus-eluting
DES.
We conducted sensitivity analyses (presented in
the Online Appendix) to evaluate the impact of
selected measures of study characteristics for
stent thrombosis, MI, CSB, and all-cause mortality
(Online Figure 3). Analyses were stratiﬁed according
to prevalence of acute coronary syndrome (ACS)
(>50%) and patients with a mean age $65 years.
Considering the marked differences in trial size
and reported outcomes of the recent DAPT trial (7),
the study-speciﬁc inﬂuence on primary outcomes
was estimated after removal of this trial from the
FIGURE 1 Meta-Analysis Flow Diagram
1 Randomized Clinical Trial
Identified from Internet
sources
7876 Citations Excluded
after screening of
study design
7885 Citations Identified from
Literature Search
10 Randomized Clinical Trials
Included
After exclusion, 10 randomized controlled (n ¼ 32,135) were included in the meta-analysis.
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1301analysis and subsequent evaluation of the change in
signiﬁcance, magnitude, and direction of the effect.
All sensitivity analyses were conducted with both a
random effects model (primary analysis method) and
a ﬁxed effects model. Analyses were conducted by
using Stata version 12.0 (Stata Corp., College Station,
Texas).
RESULTS
Of the 7,885 citations found, 10 RCTs (n ¼ 32,135)
were identiﬁed (Figure 1); characteristics of these 10
studies are summarized in Table 1. Additional details
are available in Online Table 2 and Online Figures 1
and 2.
Two RCTs (RESET [REal Safety and Efﬁcacy of
3-month dual antiplatelet Therapy following Endeavor
zotarolimus-eluting stent implantation] and OPTI-
MIZE [Optimized Duration of Clopidogrel Therapy
Following Treatment With the Zotarolimus-Eluting
Stent in Real-World Clinical Practice]) evaluated 3
months versus 12 months of DAPT (14,15). In the
OPTIMIZE trial, second-generation DES were used in
100% of patients in both randomization arms. In the
RESET trial, second-generation DESwere used in 100%
of patients in the 3-month arm and in 70% in the 12-
month arm. In these 2 trials, the average age was 62
years, the prevalence of diabetes mellitus was 32%,
and 43% had ACS.
Five RCTs evaluated a 6-month versus either a
12-month DAPT regimen (ISAR-SAFE [Safety and
Efﬁcacy of Six Months Dual Antiplatelet Therapy Af-
ter Drug-Eluting Stenting], ITALIC [Is There A Life for
DES After Discontinuation of Clopidogrel], SECURITY
[Second Generation Drug-Eluting Stent Implantation
Followed by Six- Versus Twelve-Month Antiplatelet
Therapy], and EXCELLENT [Efﬁcacy of Xience/
Promus Versus Cypher to Reduce Late Loss After
Stenting]) or a 24-month DAPT regimen (PRODIGY
[Prolonging Dual Antiplatelet Treatment After
Grading Stent-Induced Intimal Hyperplasia Study])
(16–20). In the recent ITALIC and SECURITY trials,
second-generation DES were used in 100% of patients
in both randomization arms. In the EXCELLENT and
ISAR-SAFE trials, second-generation DES were used
in >70% of patients. Finally, in the PRODIGY trial,
second-generation DES were implanted in 50% of
patients, while the remainder received bare-metal
stents or ﬁrst-generation DES. Across these 5 trials,
the average patient age was 65 years, the prevalence
of diabetes mellitus was 31%, and 46% had ACS.
Three RCTs (DAPT, DES-LATE [Duration of
Clopidogrel Therapy After Drug-Eluting Stent], and
ARCTIC-Interruption [Dual-Antiplatelet TreatmentBeyond 1 Year After Drug-Eluting Stent Implanta-
tion]) explored the efﬁcacy and safety of prolonged
DAPT beyond 12 months after the original DES im-
plantation (7,21,22). Second-generation DES were
used in 30% of patients in the DES-LATE trial and in
z60% of the population in the DAPT and ARCTIC-
Interruption trials. Therefore, the mean second-
generation DES use across the studies was 51%. The
mean patient age among these 3 RCTs was 63 years,
the prevalence of diabetes mellitus was 31%, and 52%
had ACS. The mean weighted follow-up time among
all 10 RCTs was 19.6 months; the mean weighted
exposure time to antiplatelet therapy within the
S-DAPT and L-DAPT groups was 8.5 and 23.2 months,
respectively. All the endpoints of interest in each of
the trials were independently adjudicated by a
Clinical Event Committee (Online Table 3).
STENT THROMBOSIS. Rates of stent thrombosis were
reported in all trials. The overall frequency of stent
thrombosis in the S-DAPT group was 0.9% (143 of
15,997) compared with 0.5% (80 of 16,138) in the
L-DAPT group. The combined OR for stent thrombosis
with an S-DAPT regimen versus an L-DAPT regimen
was 1.71 (95% CI: 1.26 to 2.32; p ¼ 0.001) (Figure 2).
The magnitude of the effect was attenuated in
abbreviated-term DAPT studies (OR 1.20 [95% CI 0.77
to 1.88]) compared with extended-term DAPT studies
(OR: 2.22 [95% CI: 1.55 to 3.17]; p for interaction ¼
0.044). There was no evidence of statistical hetero-
geneity among studies (p heterogeneity ¼ 0.387).
The test for small-studies effect was not signiﬁcant
(p ¼ 0.905).
FIGURE 2 Stent Thrombosis and Clinically Signiﬁcant Bleeding in Randomized Clinical Trials
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1303Rates of stent thrombosis with second-generation
DES were reported in 6 RCTs (7,15,17–19,23); stent
thrombosis rates with ﬁrst-generation DES were
reported in 3 RCTs (7,19,23). The mean weighted
exposure DAPT time with S-DAPT was 7.8 and
10.9 months for second- and ﬁrst-generation DES,
respectively. Conversely, the mean weighted expo-
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e to shorter DAPT was 7.8 months for second-generation DES and
e to longer DAPT was 20.3 months for second-generation DES and
e weight of each study. CI ¼ conﬁdence interval; DAPT ¼ Dual
sus Cypher to Reduce Late Loss After Stenting; ITALIC ¼ Is There A
zed Duration of Clopidogrel Therapy Following Treatment With the
rolonging Dual Antiplatelet Treatment After Grading Stent-Induced
g Stent Implantation Followed by Six- Versus Twelve-Month
TABLE 2 IRs and Sta
Study (Ref. #)
ARCTIC-Interruption (2
DAPT (7)
DES-LATE (22)
EXCELLENT (19)
ISAR-SAFE (16)
ITALIC (17)
OPTIMIZE (15)
PRODIGY (23)
RESET (14)
SECURITY (18)
Combined
*Results expressed as 100
CI ¼ conﬁdence interval
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13047,205) with L-DAPT, yielding a combined OR of 1.54
(95% CI: 0.96 to 2.47). The stent thrombosis rates with
ﬁrst-generation DES were 2.4% (54 of 2,284) with
S-DAPT and 0.6% (14 of 2,354) with L-DAPT, yielding
a combined OR of 3.94 (95% CI: 2.20 to 7.05). The
test for interaction between DES generation and
DAPT treatment duration was highly signiﬁcant (p for
interaction ¼ 0.008).
CLINICALLY SIGNIFICANT BLEEDING. CSB rates
used different deﬁnitions across trials. The Global Use
of Strategies to Open Occluded Arteries deﬁnitions
were used in the DAPT trial; a BARC 3 or 5 bleeding
deﬁnition was used to extract CSB rates from the
SECURITY trial; and a TIMI major or minor bleeding
deﬁnition was used in the ISAR-SAFE, PRODIGY,
RESET, and ITALIC trials. In the DES-LATE and
EXCELLENT trials, the only available bleeding rate
was major TIMI type. The incidence of CSB across
all RCTs was 1.2% in the S-DAPT group (195 of
15,997) and 1.9% in the L-DAPT group (313 of 16,138),
yielding a combined OR (Figure 2) with S-DAPT
versus L-DAPT of 0.63 (95% CI: 0.52 to 0.75;
p < 0.001). Results were consistent across abbrevi-
ated- and extended-term DAPT studies. There was no
evidence of statistical heterogeneity among studies
(p heterogeneity ¼ 0.953).
TRADE-OFF BETWEEN STENT THROMBOSIS AND
BLEEDING. The overall standardized incidence risk
difference for stent thrombosis and CSB between
S-DAPT and L-DAPT (Table 2) yielded a rate difference
of –0.45 per 100 persons/year (95% CI: –0.62 to –0.28)
for CSB and 0.21 per 100 persons/year (95% CI: 0.11 to
0.31; p < 0.001) for stent thrombosis. Therefore, for
every stent thrombosis event averted with L-DAPT,ndardized IRDs for Stent Thrombosis and Clinically Signiﬁcant Bleeding
Stent Thrombosis
S-DAPT L-DAPT
IRD* 95% CI*No. of Events IR* No. of Events IR*
1) 3 0.33 0 0 0.33 –0.04 to 0.72
69 0.80 31 0.35 0.44 0.22 to 0.67
25 0.29 13 0.15 0.13 0.00 to 0.27
6 0.83 1 0.14 0.69 –0.02 to 1.41
5 0.50 4 0.40 0.10 –0.48 to 0.69
3 0.66 0 0 0.66 –0.08 to 1.40
13 0.84 12 0.77 0.06 –0.56 to 0.69
15 0.80 13 0.69 0.11 –0.44 to 0.66
2 0.19 3 0.28 –0.09 –0.50 to 0.31
2 0.29 3 0.42 –0.12 –0.75 to 0.49
— — — — 0.21 0.11 to 0.31
persons/year.
; IR ¼ incidence rate; IRD ¼ incidence risk difference; other abbreviations as in Table 1.w2.1 CSB events are estimated to occur. The Cochran-
Mantel-Haenszel test for homogeneity between
groups was not signiﬁcant (p > 0.05 for both stent
thrombosis and CSB outcomes).
MYOCARDIAL INFARCTION. MI was reported in all
trials. The incidence of MI in the S-DAPT group and
L-DAPT group was 2.6% (417 of 15,997) and 1.9% (306
of 16,138), respectively. The combined OR for MI
associated with an S-DAPT regimen versus an L-DAPT
regimen was 1.39 (95% CI: 1.20 to 1.62; p < 0.001)
(Figure 3). The magnitude of the effect was attenu-
ated in abbreviated-term DAPT studies (OR: 1.13
[95% CI: 0.88 to 1.44), compared with extended-term
DAPT studies (OR: 1.57 [95% CI: 1.30 to 1.90; p for
interaction ¼ 0.035).
STROKE. Stroke was reported according to each trial’s
protocol deﬁnition. The incidence of stroke was 1.0%
(148 of 15,997) in the S-DAPT group and 0.9% (153 of
16,138) in the L-DAPT group. The combined OR for
stroke associatedwith S-DAPT versus L-DAPTwas 0.99
(95% CI: 0.78 to 1.24; p¼0.907) (Figure 3). Results were
consistent between abbreviated- and extended-term
DAPT studies (p for interaction > 0.05).
MORTALITY. All-cause mortality was reported in all
trials, and cardiovascular mortality was reported in 8
of 10 trials. The overall incidence of all-cause mor-
tality in the S-DAPT group was 2.0% (312 of 15,997),
whereas in the L-DAPT group, it was of 2.2% (361 of
16,138). S-DAPT was associated with a numerically
lower all-cause mortality rate with a combined OR of
0.87 (95% CI: 0.74 to 1.01; p ¼ 0.073) (Figure 4). Car-
diovascular mortality rates were 1.3% (175 of 13,376)
in the S-DAPT group and 1.4% in the L-DAPT groupper 100 Persons/Year Between S-DAPT and L-DAPT
Clinically Signiﬁcant Bleeding
S-DAPT L-DAPT
IRD* 95% CI*No. of Events IR* No. of Events IR*
1 0.11 7 0.78 –0.67 –1.29 to –0.04
84 0.98 124 1.42 –0.44 –0.77 to –0.12
63 0.73 99 1.14 –0.41 –0.70 to –0.13
2 0.28 4 0.56 –0.27 –0.94 to 0.38
6 0.60 13 1.30 –0.70 –1.56 to 0.16
5 1.10 7 1.54 –0.44 –1.94 to 1.05
10 0.64 14 0.90 –0.26 –0.88 to 0.35
15 0.80 27 1.44 –0.64 –1.32 to 0.03
5 0.47 10 0.95 –0.48 –1.20 to 0.24
4 0.59 8 1.12 –0.53 –1.50 to 0.43
— — — — –0.45 –0.62 to –0.28
FIGURE 3 Myocardial Infarction and Stroke in Randomized Clinical Trials
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1305(188 of 13,500), yielding an OR for S-DAPT versus
L-DAPT of 0.94 (95% CI: 0.76 to 1.15; p ¼ 0.563).
Results were consistent between abbreviated- and
extended-term DAPT studies for both mortality end-
points (p for interaction >0.05).DISCUSSION
The main results of this meta-analysis including
>30,000 patients from RCTs are as follows: 1) L-DAPT
was associated with a lower risk of deﬁnite/probable
FIGURE 4 All-Cause and Cardiovascular Mortality in Randomized Clinical Trials
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1306stent thrombosis and MI compared with S-DAPT,
and the magnitude of the effect was attenuated in
abbreviated-term DAPT studies compared with
extended-term studies; 2) L-DAPT was associatedwith a signiﬁcantly higher risk of CSB, yielding an
excess of w2.1 CSB events for each episode of stent
thrombosis averted; 3) the beneﬁt of L-DAPT on stent
thrombosis was signiﬁcantly attenuated with use
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1307of second-generation DES compared with ﬁrst-
generation DES; and 4) a numerically lower, albeit
not statistically signiﬁcant, all-cause mortality was
observed with S-DAPT.
CURRENT KNOWLEDGE REGARDING OPTIMAL DAPT
DURATION. Optimal duration of DAPT after DES im-
plantation is an important subject of debate. Current
European Society of Cardiology and American Heart
Association/American College of Cardiology guide-
lines recommend a minimum duration of DAPT of 6 to
12 months and 12 months, respectively (1,2). Concur-
rently, certain second-generation DES types have a 3-
month DAPT indication, per the European device
regulatory agency.
Concerns regarding late and very late stent
thrombosis with ﬁrst-generation DES motivated the
scientiﬁc community to investigate the potentially
beneﬁcial role of long-term DAPT. Several observa-
tional studies and registries found a strong and
independent association between DAPT cessation and
stent thrombosis (24,25), particularly when cessation
occurs early after DES implantation (3). Importantly,
the concerns regarding stent thrombosis after stop-
ping DAPT led to the development of newer genera-
tion DES, with improved vascular healing and
re-endothelialization properties (26–28). Permanent
polymer DES and bioresorbable polymer DES have
shown improved safety compared with initial ﬁrst-
generation DES (29,30).
The improved safety of current-generation DES
constituted the basis to evaluate abbreviated regi-
mens of DAPT duration after PCI. Before the present
meta-analysis, 7 trials evaluated the safety and efﬁ-
cacy of interrupted DAPT at 3 or 6 months compared
with prolonged DAPT at 12 or 24 months (14–20).
Interestingly, a signiﬁcant increased hazard for
ischemic events with reduced DAPT duration did
not occur in any of these trials. Conversely, an in-
creased risk for bleeding events was observed in the
PRODIGY trial that compared 6 versus 24 months of
DAPT after the implantation of various stent types
(20). Therefore, in all of these RCTs, S-DAPT seemed
to be noninferior to a regimen of L-DAPT. However,
several issues must be considered when interpreting
these results. First, most of these trials were under-
powered to detect differences in hard endpoints
because of study design issues, slow enrollment,
and lower-than-expected event rates. Second, except
for the ISAR-SAFE trial, all of these studies were
open-label (not placebo controlled). Third, primary
endpoint deﬁnitions were heterogeneous, making
comparisons between trials limited and somewhat
inappropriate when ischemic and bleeding events
were included in the composite primary endpointdeﬁnition. Fourth, in some of these studies, non-
inferiority was demonstrated for margins ﬁxed as
absolute risk difference but not relative risk differ-
ence (EXCELLENT and OPTIMIZE); because the
observed active control rate was lower than ex-
pected, ﬁxing the margin in terms of absolute risk
difference may have biased the results favoring
noninferiority.
The recently published DAPT trial randomized
9,961 event-free patients after the ﬁrst year following
DES-PCI to either continue with DAPT for another 18
months or to stop the thienopyridine (7). This trial
changed the perspective on L-DAPT by demonstrating
a signiﬁcant long-term beneﬁt in stent-related and
non–stent-related thrombotic events with the pro-
longed DAPT regimen. Nevertheless, the ischemic
beneﬁt with L-DAPT was paired with an increased risk
in major bleeding and a signiﬁcantly higher non-
cardiovascular mortality. However, a recent meta-
analysis of RCTs evaluating extended DAPT in
different clinical scenarios (including PCI, atrial
ﬁbrillation, stroke, and vascular surgery) did not
support an association between all-cause, non-
cardiovascular, or cardiovascular mortality and a
longer DAPT regimen (31).
CLINICAL IMPLICATIONS. The results of the present
meta-analysis, which included all of the most recent
trials evaluating optimal DAPT duration after PCI
with DES, offer useful insights regarding the impact
of extended DAPT on clinical outcomes and on the
unfavorable role of ﬁrst-generation DES as an
important ischemic risk modiﬁer. According to our
results, L-DAPT is associated with a signiﬁcant
reduction in late stent thrombosis and MI risk in
patients undergoing PCI with DES implantation.
Importantly, after exclusion of the DAPT trial from
the analysis (the sensitivity analysis is presented in
the Online Appendix), the association between
S-DAPT and stent thrombosis was of only borderline
signiﬁcance (numerically higher, without reaching
statistical signiﬁcance) according to the more
rigorous random effects model approach. This
ﬁnding suggests that a thrombotic beneﬁt with
DAPT might become evident with longer exposure
to treatment. However, L-DAPT is a therapeutic
strategy not exempt from risk, particularly in rela-
tion to bleeding. In fact, the thrombotic beneﬁt of
L-DAPT was counterbalanced by an increase in
bleeding risk that was consistent across the exam-
ined trials. Interestingly, the risk reduction in
stent thrombosis and MI with L-DAPT did not
translate into an all-cause or cardiovascular mor-
tality beneﬁt. Conversely, L-DAPT was associated
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(without statistical signiﬁcance) compared with S-
DAPT. The validity and consistency of this ﬁnding
remain controversial.
The clinical message of the present meta-analysis
is that the trade-off between ischemic and bleeding
events with L-DAPT is a matter of concern and
should be carefully evaluated when the decision
to continue DAPT after a recommended period is
considered. We found that for each stent throm-
bosis event averted by prolonging DAPT, an excess
of 2.1 CSB events would be expected. Moreover, the
risk of late and very late stent thrombosis with
S-DAPT is notably increased in patients receiving a
ﬁrst-generation DES, which are used rarely (if at
all) at the present time. Assuming a comparable
bleeding risk across stent generations with provi-
sion of prolonged DAPT, our ﬁndings suggest that
the risk/beneﬁt ratio for extending DAPT has an
important variation according to type of DES used.
In the current cardiology practice, only the results
of second-generation DES are clinically applicable.
Accordingly, the prevention of a single episode of
late stent thrombosis will require exposing a
larger number of patients with a second-generation
DES to potentially serious bleeding harm (Central
Illustration). This difference is clinically relevant
when the decision to prolong DAPT after the
initial recommended period is being considered.
The interaction between DAPT duration and DES
generation was previously described by Camen-
zind et al. (32); in the absence of DAPT prolonged
beyond 1 year, stent thrombosis at 3 years was
signiﬁcantly lower with a second-generation DES,
whereas no differences between ﬁrst- and second-
generation DES were observed with extended-term
DAPT treatment.
The counterbalancing inﬂuences of preventing
thrombosis while simultaneously increasing bleeding
risk may account for the lack of mortality beneﬁt (and
possibly the suggestion of increased all-cause mor-
tality) observed with extended DAPT duration.
Beyond risk of stent thrombosis, it would still be
acceptable to use an extended DAPT regimen; the
goal would be to offer a broader coronary athero-
thrombotic beneﬁt in terms of MI protection (often
unrelated to a stent thrombosis event) in patients
who are tolerating the initially recommended DAPT
duration well and have been judged to be at mod-
erate or high ischemic risk along with having a low
bleeding hazard. Therefore, the optimal duration of
DAPT with current-generation DES outside ACS re-
mains undeﬁned, and the timing of interruption ofthe thienopyridine can be as short as 3 or 6 months
after stent implantation. Finally, considering the
continuous device and pharmacology evolution,
further trials are needed to evaluate optimal dura-
tion with use of the current- and forthcoming-gen-
eration DES and the high-potency antiplatelet
drugs.
STUDY LIMITATIONS. The main limitation of the
present study is the lack of patient-level data, which
does not allow us to evaluate ischemic and net com-
posite endpoints or perform time-to-event analyses
and covariate-adjusted analyses among different
types of DAPT discontinuation and durations.
Patient-level data would allow identifying indepen-
dent predictors of ischemic and bleeding events using
different durations of DAPT as a risk modiﬁer. In
addition, the different studies did not explicitly
report results of all the clinical endpoints according to
stent type.
Second, the lower rate of stent thrombosis
observed with second-generation DES could be
related to the fact that the duration of the RCTs with
more frequent second-generation DES use were those
with shorter term follow-up; therefore, the lower
exposure and follow-up time might have accounted
for the lower event rates. However, lower incidence
of late and very late stent thrombosis with second-
generation DES compared with older generation DES
is strongly supported by earlier clinical evidence
(28,29).
Third, we did not perform a risk/beneﬁt trade-off
analysis between MI and bleeding because clinical
event severity was not available in the studies, and
thus the external validity of such results would be
poor. Fourth, another limitation of the meta-
analysis is the substantial diversity in protocol
designs of the included abbreviated- and extended-
term DAPT RCTs; caution is therefore required in
interpreting any overall effect estimate for S-DAPT
versus L-DAPT. Finally, we found heterogeneity at
the sensitivity analysis regarding the effect of S-
DAPT on stent thrombosis following exclusion of
the DAPT trial. This ﬁnding suggests that the
thrombotic beneﬁts associated with DAPT become
evident over time and that the overall effect of
S-DAPT on stent thrombosis might have been
attenuated by the abbreviated-term DAPT trials.
Therefore, to clarify the effect of extended DAPT on
ischemic and bleeding outcomes, and eventually
survival, additional randomized data evaluating
longer DAPT duration in contemporary clinical
practice are needed.
PERSPECTIVES
COMPETENCIES IN MEDICAL KNOWLEDGE: DAPT is asso-
ciated with protection against ischemic events but increases the
risk of bleeding in patients with DES. The beneﬁt of extended
DAPT is strongly signiﬁcant in patients treated with ﬁrst-
generation DES and attenuated with the use of current second-
generation DES.
COMPETENCY IN PATIENT CARE: Physicians should care-
fully evaluate patients’ ischemic and bleeding risks and consider
the type of stent implanted, in addition to how well therapy has
been tolerated, in determining how long to extend DAPT
(beyond an initial period) after DES implantation.
TRANSLATIONAL OUTLOOK: Additional randomized trials
are needed to evaluate the optimum duration of DAPT in patients
with the latest generation DES devices and high-potency anti-
platelet drugs.
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1309CONCLUSIONS
S-DAPT was associated with signiﬁcantly higher def-
inite or probable stent thrombosis rates compared
with L-DAPT. The magnitude of the effect of S-DAPT
on stent thrombosis was signiﬁcantly attenuated with
the use of second-generation DES. However, the
thrombotic beneﬁt of L-DAPT was paired with a
higher risk of bleeding and numerically higher all-
cause mortality. The results of the present meta-
analysis indicate that the risk/beneﬁt ratio between
stopping or continuing DAPT after an initially rec-
ommended period should be carefully individualized
considering the trade-off between ischemic and
bleeding future risk.
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